707 results on '"Rybicki, L"'
Search Results
2. Association of socioeconomic status with autologous hematopoietic cell transplantation outcomes for lymphoma
Catalog
Books, media, physical & digital resources
3. Risk factors for recurrent Clostridium difficile infection in allogeneic hematopoietic cell transplant recipients
4. Association of socioeconomic status with long-term outcomes in 1-year survivors of allogeneic hematopoietic cell transplantation
5. Prognostic significance of pre-transplant quality of life in allogeneic hematopoietic cell transplantation recipients
6. Racial differences in allogeneic hematopoietic cell transplantation outcomes among African Americans and whites
7. Outcomes after autologous SCT in lymphoma patients grouped by weight
8. Elective Neck Treatment for Clinically Node-Negative Salivary Gland Cancer: Observation, Neck Dissection, or Neck Irradiation?
9. Outcomes of autologous hematopoietic cell transplantation in primary amyloidosis after bortezomib-based induction therapy
10. Quality of life and outcomes in patients⩾60 years of age after allogeneic hematopoietic cell transplantation
11. Risk factors for vancomycin-resistant enterococcus bacteremia and its influence on survival after allogeneic hematopoietic cell transplantation
12. Gefitinib in definitive management of esophageal or gastroesophageal junction cancer: a retrospective analysis of two clinical trials
13. Validating the positive impact of in-hospital lay care-partner support on patient survival in allogeneic BMT: a prospective study
14. Intravenous compared with oral busulfan as preparation for allogeneic hematopoietic progenitor cell transplantation for AML and MDS
15. Fludarabine as a risk factor for poor stem cell harvest, treatment-related MDS and AML in follicular lymphoma patients after autologous hematopoietic cell transplantation
16. Etoposide plus G-CSF priming compared with G-CSF alone in patients with lymphoma improves mobilization without an increased risk of secondary myelodysplasia and leukemia
17. Apheresis days required for harvesting CD34+ cells predicts hematopoietic recovery and survival following autologous transplantation
18. BU- vs TBI-based conditioning for adult patients with ALL
19. Comparison of outcomes after auto-SCT for patients with relapsed diffuse large B-cell lymphoma according to previous therapy with rituximab
20. Comparison of donor chimerism following myeloablative and nonmyeloablative allogeneic hematopoietic SCT
21. Are backup BM harvests worthwhile in unrelated donor allogeneic transplants?
22. Quality of life and outcomes in patients ≥ 60 years of age after allogeneic hematopoietic cell transplantation
23. Ethical reasoning about patient eligibility in allogeneic BMT based on psychosocial criteria
24. Utility of the psychosocial assessment of candidates for transplantation (PACT) scale in allogeneic BMT
25. Donor T-cell chimerism and early post-transplant cytomegalovirus viremia in patients treated with myeloablative allogeneic hematopoietic stem cell transplant
26. A randomized trial of etoposide and G-CSF with or without rituximab for PBSC mobilization in B-cell non-Hodgkin's lymphoma
27. 400 cGy TBI with fludarabine for reduced-intensity conditioning allogeneic hematopoietic stem cell transplantation
28. Influence of killer immunoglobulin-like receptor/HLA ligand matching on achievement of T-cell complete donor chimerism in related donor nonmyeloablative allogeneic hematopoietic stem cell transplantation
29. Effect of prior rituximab on high-dose therapy and autologous stem cell transplantation in follicular lymphoma
30. Elevated lactate dehydrogenase is an adverse predictor of outcome in HLA-matched sibling bone marrow transplant for acute myelogenous leukemia
31. Patients mobilizing large numbers of CD34+ cells (‘super mobilizers’) have improved survival in autologous stem cell transplantation for lymphoid malignancies
32. Autologous hematopoietic stem cell transplantation in peripheral T-cell lymphoma using a uniform high-dose regimen
33. Survival of AML patients receiving HLA-matched sibling donor allogeneic bone marrow transplantation correlates with HLA-Cw ligand groups for killer immunoglobulin-like receptors
34. Downregulation of topoisomerase IIβ in myeloid leukemia cell lines leads to activation of apoptosis following all-trans retinoic acid-induced differentiation/growth arrest
35. Allogeneic BMT and patient eligibility based on psychosocial criteria: a survey of BMT professionals
36. GvHD-free, relapse-free survival after reduced-intensity allogeneic hematopoietic cell transplantation in older patients with myeloid malignancies
37. Dendritic cells in autologous hematopoietic stem cell transplantation for diffuse large B-cell lymphoma: graft content and post transplant recovery predict survival
38. CD8+ T-cell-depleted, matched unrelated donor, allogeneic bone marrow transplantation for advanced AML using busulfan-based preparative regimens
39. Steroids prevent engraftment syndrome after autologous hematopoietic stem cell transplantation without increasing the risk of infection
40. A prospective randomized trial comparing cyclosporine and short course methotrexate with cyclosporine and mycophenolate mofetil for GVHD prophylaxis in myeloablative allogeneic bone marrow transplantation
41. Clinical outcomes of patients with impaired left ventricular ejection fraction undergoing autologous bone marrow transplantation: can we safely transplant patients with impaired ejection fraction?
42. Prognostic importance of the platelet count 100 days post allogeneic bone marrow transplant
43. Long-term follow-up of a prospective randomized trial comparing CYA and MTX with CYA and mycophenolate mofetil for GVHD prophylaxis in myeloablative sibling donor hematopoietic cell transplantation
44. Skeletal trauma preceding the development of plasma cell dyscrasia: Eight case reports and review of the literature
45. Evaluation of nutritional status in advanced metastatic cancer
46. Etanercept therapy in patients with advanced primary amyloidosis
47. Timed-sequential chemotherapy with concomitant granulocyte colony-stimulating factor for newly diagnosed de novo acute myelogenous leukemia
48. Etoposide (VP-16) plus G-CSF mobilizes different dendritic cell subsets than does G-CSF alone
49. Clinicopathologic features and treatment outcomes of patients with human epidermal growth factor receptor 2-positive adenocarcinoma of the esophagus and gastroesophageal junction
50. A multivariable analysis of factors influencing mucositis after autologous progenitor cell transplantation
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.